| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Microbiology and Immunology and
Medicine, University of Miami School of Medicine, Miami, FL 33101;
Sylvester Cancer Center, Miami, FL 33101; and
Department of Biomedical Sciences, Florida Atlantic University, Boca Raton, FL 33431
Matrix metalloproteinase-9 (MMP-9), a matrix-degrading enzyme, is crucial in tumor invasion and metastasis and is implicated in leukocyte extravasation. In this report, we demonstrate that during growth of the D1–7,12-dimethylbenzanthracene-3 mammary tumor in BALB/c mice, there is progressive up-regulation of MMP-9 in splenic T cells at both the transcriptional and translational levels. Our previous work has identified several factors produced by this tumor, including PGE2, GM-CSF, and phosphatidyl serine; however, none of these agents induces increased production of MMP-9 by normal splenic T cells. Although not produced by the tumor, TNF-
and IL-6 are up-regulated in both macrophages and B cells in tumor-bearing mice. Exposure of normal T cells to these two cytokines, however, also fails to up-regulate MMP-9 production. Vascular endothelial growth factor (VEGF) is produced by many tumors, and we determined that the mammary tumor used in our studies expresses high levels of this angiogenic growth factor. Importantly, splenic T cells from tumor bearers constitutively produce increased amounts of VEGF, and treatment of normal T cells with VEGF results in up-regulated MMP-9 production. Of crucial importance is the finding that tumor-infiltrating T cells also produce high levels of VEGF and MMP-9. Our studies indicate that VEGF can act directly on T lymphocytes and that elevated VEGF levels may contribute to the aberrant MMP-9 secretion by mammary tumor bearers’ T cells.
This article has been cited by other articles:
|
|
 |
|
  M. E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L. M. HERBERT, and D. M. LOPEZ Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors Anticancer Res, June 1, 2009; 29(6): 2051 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Torroella-Kouri, R. Silvera, D. Rodriguez, R. Caso, A. Shatry, S. Opiela, D. Ilkovitch, R. A. Schwendener, V. Iragavarapu-Charyulu, Y. Cardentey, et al. Identification of a Subpopulation of Macrophages in Mammary Tumor-Bearing Mice That Are Neither M1 nor M2 and Are Less Differentiated Cancer Res., June 1, 2009; 69(11): 4800 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Jani, N. Singh, C. Jenkins, S. Raghava, Y. Mo, S. Amin, U. B. Kompella, and B. K. Ambati Nanoparticles Sustain Expression of Flt Intraceptors in the Cornea and Inhibit Injury-Induced Corneal Angiogenesis Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2030 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stefanidakis and E. Koivunen Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression Blood, September 1, 2006; 108(5): 1441 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Malik, K. Day, I. Perrault, D.S. Charnock-Jones, and S. K. Smith Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-{alpha} in menstrual endometrium and effluent in women with menorrhagia Hum. Reprod., August 1, 2006; 21(8): 2158 - 2166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rodriguez-Pla, J. A. Bosch-Gil, J. Rossello-Urgell, P. Huguet-Redecilla, J. H. Stone, and M. Vilardell-Tarres Metalloproteinase-2 and -9 in Giant Cell Arteritis: Involvement in Vascular Remodeling Circulation, July 12, 2005; 112(2): 264 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Herbert, J. F. Grosso, M. Dorsey Jr., T. Fu, I. Keydar, M. A. Cejas, D. H. Wreschner, N. Smorodinski, and D. M. Lopez A Unique Mucin Immunoenhancing Peptide with Antitumor Properties Cancer Res., November 1, 2004; 64(21): 8077 - 8084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Grosso, L. M. Herbert, J. L. Owen, and D. M. Lopez MUC1/sec-Expressing Tumors Are Rejected In Vivo by a T Cell-Dependent Mechanism and Secrete High Levels of CCL2 J. Immunol., August 1, 2004; 173(3): 1721 - 1730. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
